技术文章

6-Bromo-4-methylquinazoline: Properties, Uses & Key Facts

6-Bromo-4-methylquinazoline is a halogenated bicyclic heteroaromatic compound widely employed as a versatile building block in medicinal chemistry and pharmaceutical synthesis.

CAS-like Identifier / Internal Reference
BD248176 (Aladdin internal reference)
Molecular Framework
Quinazoline (benzopyrimidine) bicyclic aromatic ring system
Key Substituents
Bromine at position 6; methyl group at position 4
Primary Research Use
Synthetic intermediate for kinase inhibitors and other bioactive heterocyclic compounds
Reactivity Highlights
C–Br bond amenable to palladium-catalyzed cross-coupling (Suzuki, Heck, Buchwald–Hartwig) and nucleophilic substitution
Aladdin SKU
B589920

Chemical Identity and Structure

6-Bromo-4-methylquinazoline belongs to the quinazoline family of bicyclic heteroaromatic compounds, which consist of a benzene ring fused to a pyrimidine ring. The compound carries a bromine substituent at the 6-position of the aromatic ring and a methyl group at the 4-position adjacent to the ring nitrogen. This substitution pattern imparts distinct electronic and steric properties that make the molecule highly amenable to further chemical elaboration.

The presence of two ring nitrogen atoms (N-1 and N-3) in the quinazoline core contributes to the electron-deficient nature of the aromatic system, enhancing the susceptibility of the C-4 position to nucleophilic attack and making the C–Br bond at C-6 reactive toward metal-catalyzed transformations. The methyl group at C-4 simultaneously provides a handle for potential oxidation or functionalization while modulating the overall electronic density of the scaffold.

Synthetic Utility and Key Reactions

The C–Br bond in 6-Bromo-4-methylquinazoline is the primary handle for chemical diversification. Palladium-catalyzed cross-coupling reactions—including Suzuki–Miyaura (with aryl or heteroaryl boronic acids), Heck, and Buchwald–Hartwig amination reactions—can be applied to introduce a wide range of aryl, vinyl, or amino substituents at the 6-position. These transformations are central to generating compound libraries for structure–activity relationship (SAR) studies.

Nucleophilic aromatic substitution reactions are also accessible given the electron-deficient character of the quinazoline ring. Additionally, the 4-methyl group can serve as a precursor for benzylic functionalization under appropriate oxidative or radical conditions, expanding the synthetic versatility of this scaffold.

Because quinazoline derivatives are among the most clinically validated scaffolds in drug discovery—appearing in approved EGFR inhibitors such as gefitinib and erlotinib—6-Bromo-4-methylquinazoline is frequently used as a starting material or intermediate in the preparation of novel kinase inhibitor candidates.

Research and Pharmaceutical Applications

In medicinal chemistry, 6-Bromo-4-methylquinazoline serves primarily as a pharmacophore precursor. Researchers leverage its reactive bromine and the electron-deficient quinazoline core to synthesize target compounds designed to inhibit specific kinases, particularly those in oncology-related signaling pathways. The quinazoline scaffold has well-documented interactions with the ATP-binding pockets of receptor tyrosine kinases, making derivatives of this compound relevant to anticancer drug research.

Beyond kinase biology, quinazoline-based compounds have been investigated for a range of biological activities including antimicrobial, anti-inflammatory, and antifungal properties. 6-Bromo-4-methylquinazoline provides a convenient entry point into this chemical space, enabling researchers to systematically explore the impact of substituent variation on biological potency and selectivity.

In chemical biology, the compound may also be used to prepare fluorescent probes or affinity reagents when conjugated to appropriate reporter groups, expanding its utility beyond classical drug synthesis.

Handling, Storage, and Laboratory Safety

As a brominated heteroaromatic compound, 6-Bromo-4-methylquinazoline should be handled with standard laboratory precautions. Personnel should wear appropriate personal protective equipment (PPE) including gloves, safety glasses, and a laboratory coat. Operations involving fine powders should be conducted in a well-ventilated fume hood to avoid inhalation of particulates.

The compound should be stored in a cool, dry environment away from light, moisture, and incompatible reactive materials such as strong oxidizers or reducing agents. Sealed containers under an inert atmosphere (e.g., nitrogen or argon) are recommended for long-term storage to prevent potential hydrolysis or oxidation of the sensitive quinazoline core.

Users should consult the Safety Data Sheet (SDS) provided by Aladdin Scientific (SKU B589920) for complete hazard classification, first-aid measures, disposal guidance, and regulatory information applicable to their jurisdiction before use.

Frequently asked questions

What makes 6-Bromo-4-methylquinazoline useful in drug discovery?

The compound combines a drug-validated quinazoline core with a reactive bromine at C-6 and a methyl group at C-4. This allows rapid diversification via palladium-catalyzed cross-coupling and other reactions, enabling efficient synthesis of kinase inhibitor candidates and other bioactive molecules for SAR studies.

Which cross-coupling reactions are compatible with 6-Bromo-4-methylquinazoline?

The C–Br bond at the 6-position is well-suited for Suzuki–Miyaura coupling with boronic acids, Heck reactions with alkenes, and Buchwald–Hartwig amination with amines, all under standard palladium catalysis conditions. Nucleophilic aromatic substitution may also be applicable given the electron-deficient ring system.

How should 6-Bromo-4-methylquinazoline be stored to maintain stability?

Store the compound in a sealed container under an inert gas (nitrogen or argon), in a cool and dry location away from light and moisture. These conditions minimize the risk of hydrolysis or oxidative degradation of the quinazoline ring system over time.

Is 6-Bromo-4-methylquinazoline related to any approved drug scaffolds?

Yes. The quinazoline core is the defining scaffold of several clinically approved kinase inhibitors, most notably EGFR inhibitors such as gefitinib and erlotinib. While 6-Bromo-4-methylquinazoline itself is a research intermediate rather than a drug, its structural similarity to these pharmacophores makes it a valuable starting point for designing new therapeutic candidates.

References

  1. Arshad, M. F. et al. Quinazoline: A versatile scaffold in medicinal chemistry. Journal of Heterocyclic Chemistry, 2022 (general review; specific volume/page needs verification).
  2. Pao, W. & Chmielecki, J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer, 2010 (gefitinib/erlotinib quinazoline scaffold reference; exact citation details need verification).
  3. Aladdin Scientific. Product page: 6-Bromo-4-methylquinazoline, SKU B589920. Aladdin Scientific catalog (internal reference BD248176).

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.

目录: 技术文章

Da — 若无特别说明,分子量单位默认为道尔顿。   Mw — 重均分子量。   Mn — 数均分子量。

产品仅供科研与开发使用,不用于人体、动物、诊断或治疗。

引用本文

阿拉丁科学.《6-Bromo-4-methylquinazoline: Properties, Uses & Key Facts》. 阿拉丁知识库,更新于 2026年10月6日。 https://www.aladdin-e.com/zh_cn/faqs/6-bromo-4-methylquinazoline-properties-uses-key-facts-en.html
这篇文章对您有帮助吗? Yes No 有 4 人觉得有帮助